24 results about "Serum concentration" patented technology

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

The invention belongs to the technical field of microorganisms and compound nutrients, and particularly relates to a postbiotic preparation and composition for improving activity of gamma-aminobutyric acid and promoting calcium absorption and application of the postbiotic preparation and composition in sleep improvement and bone health. Through the synergistic effect of the specific metagen preparation and the gamma-aminobutyric acid, the multi-dimensional technical breakthrough is realized, and the physiological activity and the application value are remarkably improved. In the aspect of bioavailability, the intestinal barrier function is improved and the pH value of the intestinal tract is adjusted to be weakly acidic through the postbiotics, so that the concentration of serum GABA is increased by 2-3 times compared with that of single use, and the calcium absorption rate is increased from 30% to 55-60%. And on the aspect of function synergy, the limitation of single effect in the prior art is broken through, dual-function synergy of'sleep regulation-bone health 'is realized, meanwhile, the vicious circle of'poor sleep-calcium loss' is improved, and good practical application value is achieved.

The disclosure provides improved human FGF23-binding antibodies with increased affinity for human FGF23 as compared to burosumab, enabling reduced dosing frequency, improving convenience of therapy, and achieving higher efficacy compared to burosumab, without compromising safety.

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The invention discloses a method for evaluating gastric cancer prognosis by using peripheral blood inflammation related markers, and belongs to the technical field of smart medical treatment. The method comprises the following steps: firstly, constructing an immune state model based on a ratio of neutrophil to lymphocyte and a ratio of platelet to lymphocyte, and outputting an immune state coefficient; constructing a nutrition state model based on serum albumin, globulin concentration and ratio of albumin to globulin, and outputting a nutrition state coefficient; then combining the coefficients with the serum IL-35 and IL-37 concentrations to construct an inflammation risk model, and outputting an inflammation risk coefficient; meanwhile, a behavioral environment state model is constructed based on the daily salt intake and the smoking age limit of the patient, and a behavioral environment state coefficient is output; and finally, integrating the inflammation risk coefficient, the behavior environment state coefficient and the prognosis nutrition index, and obtaining a prognosis evaluation coefficient through a prognosis state evaluation model. Through multi-dimensional and non-invasive index integration and modeling analysis, accurate, economic and convenient evaluation of gastric cancer prognosis is realized.

The present application relates to the method and the used heat lung clear granules of treating pneumonia, one aspect, it is related to the method such as investigating the effect of heat lung clear granules in treating pneumonia by determining serum TNF-alpha concentration, including the steps: mice are randomly divided, atomized modeling is used LPS, after modeling, heat lung clear granules are given by gavage, blood is taken from mice, serum is collected, at least one of the following items is determined: lung index, TNF-alpha, IL-1beta, LI-6, PGE2 content in serum, and the statistical result of the treatment effect of heat lung clear granules on mice with pneumonia is obtained according to the detection data.The present application also provides the use of heat lung clear granules as a pneumonia treatment drug.The present application shows that heat lung clear granules are a very good pneumonia treatment drug.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CST6 as a lung cancer brain metastasis early diagnosis marker. The core of the invention is to confirm that CST6 is used as a marker for early diagnosis and prediction of brain metastasis of lung cancer for the first time. In experimental verification, the CST6 protein expression quantity of the lung cancer cell strain H1975-BrM with high brain metastasis potential is remarkably higher than that of a common cell strain, an animal model further shows that overexpression of CST6 can promote formation of brain metastasis, and knock-down expression can inhibit metastasis capacity; clinical sample analysis shows that the serum CST6 concentration of brain metastasis patients is far higher than that of non-metastasis patients and healthy people, and the diagnostic value of CST6 is supported. In the aspect of diagnosis efficiency, the area under the ROC curve of the serum CST6 reaches 0.848, and high accuracy is shown. On the whole, the clinical blank is filled, and a reliable tool is provided for non-invasive lung cancer brain metastasis risk management.

The present disclosure describes a method for preventing or treating an abnormal mammary gland cytopathy characterized by cell proliferation in a subject. The method comprises administering to the subject an effective amount of an androgen agent in combination with an effective amount of an aromatase inhibitor, increasing the concentration of the androgen agent in serum to a level to increase the intramammary concentration of androgen in the mammary gland resulting from the action of 5 alpha-reductase on the androgen agent, the increased intramammary concentration of the androgen induces inhibition of c-Myc and / or mTOR expression or activity in the mammary gland associated with a lower intramammary concentration of the androgen. The increase in the serum concentration of the androgen agent and the increase in the intramammary concentration of the androgen are maintained for a predetermined period of time without substantially increasing the concentration of the androgen in the serum of the subject. Furthermore, the use of the aforementioned androgen and aromatase inhibitors for reducing the risk of breast cancer progression to hormone-resistant breast cancer, reducing the risk of HER2-positive breast cancer becoming insensitive to targeted HER-2 anti-cancer drug therapy, and for inducing inhibition of c-Myc and / or mTOR expression and / or activity is also described. In embodiments, the androgen agent may be testosterone and androgen 5 [alpha]-dihydrotestosterone (DHT).

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

The invention discloses a health risk assessment method for association of PFAS concentration and cardiovascular-kidney-metabolic syndrome, and the method comprises the following specific implementation processes: obtaining concentration data of PFAS in serum of a crowd and related data of blood physicochemical and physicochemical measurement, and calculating the ten-year cardiovascular disease risk and renal function condition of a human body. The heart and kidney metabolic syndrome condition of an individual is staging to judge the health condition, and a threshold value of health risk improvement is established according to the serum PFAS concentration and related data of all samples in combination with the health condition. According to the method, accurate quantitative evaluation of multi-dimensional health risks is realized, the comprehensive influence of PFAS on human health is more comprehensively reflected through the heart and kidney metabolic syndrome, the health risk threshold of serum PFAS exposure is provided, and early warning is provided for high-risk people.

Methods are described for treating a localized infection of living tissue in a human patient in need thereof, which may include locally administering a daily dose of at least one antibiotic that substantially exceeds the maximum recommended daily dose of the at least one antibiotic, and providing a peak or trough serum concentration of the at least one antibiotic that is below the maximum safe serum concentration level.

The present application relates to a compound for reducing serum concentration of RBP4, a stereoisomer, a deuterated derivative, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of a stereoisomer or an acceptable salt of a deuterated derivative, and a method for preparing the compound, a composition and use thereof.

This invention provides a method and system for predicting the potential of bovine in vitro embryo production based on AMH concentration, relating to the field of livestock reproductive technology. The method includes: obtaining a blood sample from a donor cow before the start of the in vitro embryo production cycle; performing serum separation processing on the blood sample to obtain a serum sample; detecting the anti-Müllerian hormone concentration in the serum sample to obtain a serum AMH concentration value; and predicting the number of follicles in the donor cow based on the serum AMH concentration value using a cubic polynomial regression model. This invention establishes serum AMH concentration as an objective biomarker for predicting bovine in vitro embryo production potential and constructs a corresponding quantitative prediction model, achieving early, non-invasive, and quantitative prediction of the individual potential of donor cows before incurring high production costs.

According to the application of the lucid ganoderma extract tablet in resisting depression, provided by the invention, the lucid ganoderma extract tablet can be used for remarkably increasing the preference degree of rats on sweet water, remarkably increasing the activity distance and standing times of the rats, remarkably reducing the immobility time of the rats, remarkably reducing the concentration of serum CORT of the rats and remarkably increasing the concentration of hippocampus and prefrontal cortex 5-HT of the rats; the concentration of rat hippocampus and prefrontal cortex NE is obviously increased, and the concentration of rat hippocampus and prefrontal cortex DA is obviously increased, so that the anti-depression effect is achieved.

To provide a formulation having a novel sustained release multi-phasic concentration pattern, particularly a formulation that can be used to reduce mammographic breast density and / or breast stiffness in warm-blooded animals.SOLUTION: For example, the formulation may include administration of an effective amount of an androgenic agent and an effective amount of an aromatase inhibitor to a subject, and provides a sustained release multiphasic concentration pattern in the blood of the subject over time, as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor, and particularly improves breast tissue stability and / or increases androgen receptor expression levels.SELECTED DRAWING: Figure 2

The utility model relates to a portable blood taking card for rapidly detecting the serum concentration of vitamin K2, which comprises a card shell and a blood storage strip, and is technically characterized in that the card shell is rectangular and is provided with an opening in the side, an upper support cavity corresponding to the blood storage strip and a cooling object accommodating cavity positioned at the lower part of the upper support cavity are arranged in the card shell, a support shoulder is arranged between the upper support cavity and the cooling object accommodating cavity, and the support shoulder is provided with a clamping groove. The blood storage strip is provided with a blood storage cavity, a blood injection assembly communicated with the blood storage cavity is arranged on the upper surface of the blood storage strip, the edge of the lower surface of the blood storage strip is supported on the upper surface of the supporting shoulder, a large through hole is formed in the middle of the lower surface of the blood storage strip, and an anti-seepage protection film for blocking the large through hole is attached to the inner bottom face of the blood storage strip. Cooling gel used for being bonded with the blood storage strip and the lower surface of the anti-seepage protection film is sealed in the packaging bag in a sealed mode. Compared with an existing blood taking card, the vitamin K2 blood taking card ensures the preservation requirement before the concentration of vitamin K2 is detected, improves the detection accuracy, is convenient to carry and is suitable for independent and rapid inspection.

The invention provides an SNP (Single Nucleotide Polymorphism) molecular marker related to pig immune traits, which is located at the 54707402 site of the sixth chromosome of a pig reference genome Susscrofa.Sscrofa11.1 version, and has T / C polymorphism; wherein the C allelic group is used as a dominant allele for improving the serum interferon gamma concentration, and the serum IFN-gamma concentration of a pig individual with the genotype of CC is obviously higher than that of an individual with the genotype of TT or TC; the molecular marker has the beneficial effects that the technical scheme provided by the invention provides a new molecular marker resource with clear genetic effect, reliable typing method and good cross-population stability for pig breeding for disease resistance.

The invention discloses a biomarker combination for screening heart failure pleural effusion as well as application, a system, equipment and a medium. The biomarker combination comprises palmitoyl carnitine, stearoyl carnitine, octadecadienoyl carnitine, and the hydrothorax serum concentration ratio of at least one long-chain acyl carnitine in octadecaenoyl carnitine. The biomarker combination provided by the invention has higher clinical value in screening or auxiliary diagnosis of heart failure pleural effusion.

The application discloses a sample analysis method, device and computer readable storage medium, wherein the sample analysis method comprises: obtaining a to-be-tested reaction curve of a mixed solution; wherein a to-be-tested sample solution and a reagent solution react to form the mixed solution, and the to-be-tested reaction curve represents a corresponding relationship between an absorbance value of the mixture and time; based on a characteristic parameter of the to-be-tested reaction curve, determining an estimated concentration value of the to-be-tested sample solution in a pre-established calibration curve; based on the estimated concentration value, determining a corresponding true concentration value in a pre-established hook effect curve; and determining a serum concentration of the to-be-tested sample solution according to the true concentration value. In this way, the detection cost can be reduced, and the detection efficiency can be improved.

The application discloses a Hashimoto's thyroiditis model, a construction method thereof and an antigen, and the construction method comprises the following steps: preparing a pig thyroid lyophilized powder; selecting 8-week-old EAT susceptible strain CBA / J female mice, and injecting phosphate buffered saline solutions containing the pig thyroid lyophilized powder at the 0th day, the 7th day and the 14th day after 8 weeks; injecting phosphate buffered saline solutions containing lipopolysaccharide at a predetermined time interval; when the EAT susceptible strain CBA / J female mice are 12 weeks old, the modeling effect is measured from thyroid pathological morphology and EAT scores, serum TgAb concentration, serum TPOAb concentration and the number of each T lymphocyte subpopulation in the spleen. After the mice are continuously injected with the phosphate buffered saline solutions containing the pig thyroid lyophilized powder and the lipopolysaccharide for three times through the tail vein, the mice produce autoantibodies, and obvious lymphatic infiltration appears in the thyroid tissue, which indicates that the pig thyroid lyophilized powder can induce the occurrence of Hashimoto's thyroiditis, and a new thought is provided for the pathogenesis of Hashimoto's thyroiditis.

A method of estimating glomerular filtration rate of a feline can include measuring a blood sample of a feline for blood serum concentrations of pseudouridine and acetylthreonine, and optionally phenylacetylglutamine, and / or tryptophan, and also calculating a blood serum level product. The method can also include applying a feline factor as a multiple to the blood serum level product resulting in an estimated glomerular filtration rate. Calculating the blood serum level product can be based on a first weighted value based upon the blood serum concentration of pseudouridine, a second weighted value based upon the blood serum concentration of acetylthreonine,, an optional third weighted value based upon the blood serum concentration of phenylacetylglutamine, and an optional fourth weighted value based upon the blood serum concentration of tryptophan.

The invention belongs to the technical field of ST cell full suspension culture, and particularly relates to a rapid domestication method suitable for serum-free suspension culture of ST cells, which is characterized by comprising the following steps: (1) gradient domestication stage: according to a conventional gradient domestication method, reducing the concentration of adherent ST cell culture serum to 2%; (2) low-serum monoclonal screening: screening monoclonal cell strains with growth advantages in a low-serum culture medium through a limited dilution method, and carrying out enlarged culture; and (3) serum-free suspension adaptive domestication: digesting the amplified and cultured monoclonal cells, and transferring the digested monoclonal cells into a shake flask for serum-free suspension adaptive domestication. The invention provides an efficient and low-cost ST cell serum-free suspension domestication method, which can completely eliminate adherent dependence, improve cell density to 8.0 * 10 < 6 > cells / ml, ensure that the motility rate is greater than 93% after continuous passage of 160 generations, and verify genetic stability and cryopreservation adaptability.

The invention provides a low-serum transition multiplication culture method and a culture medium for CD16 high-expression V [gamma] 9V [delta] 2T cells, and belongs to the technical field of cell culture.The culture method comprises the steps that the serum concentration of a culture environment is firstly gradually reduced, induction of interleukin-15 and regulation and control of an antioxidant are combined, then the V [gamma] 9V [delta] 2T cells are massively amplified through a low-serum culture environment, and a large amount of CD16 is expressed; the low-serum culture environment is a culture environment with the serum content equal to or lower than 2%, and by combining low-serum transition, IL-15 induction of CD16 expression, antioxidant reduction of ROS and efficient amplification, high-proportion CD16 + phenotypes are maintained in the amplification process, and the ROS level in cells is reduced. The compound can be used for immune cell therapy and immune cell combined therapy related to antibody dependent cytotoxic action (ADCC), and has potential of function optimization and clinical application.

The present disclosure relates to formulations, delivery systems, and / or methods of use having novel sustained release multi-phasic concentration patterns that can be used, among other things, to reduce mammographic breast density and / or breast stiffness in a warm-blooded animal. For example, the formulations can comprise: administering to a subject an effective amount of an androgenic agent and an effective amount of an aromatase inhibitor that provides a sustained release multi-phasic concentration pattern over time in the blood of the subject, as measured by serum concentration of the androgenic agent and plasma concentration of the aromatase inhibitor, and that improves, among other things, breast tissue stability and / or increases androgen receptor expression levels. The present disclosure also relates to the use of an effective amount of an androgenic agent in combination with an effective amount of an aromatase inhibitor for preventing or treating autoimmune inflammatory breast (AIM) in a patient in need thereof. Autoimmune inflammatory breast includes conditions of idiopathic inflammatory giant breast, plasma cell mastitis, granulomatous mastitis.